Product availability, name and indicated use may vary by country. Please contact your local Ipsen website to learn more about products available in your country.
Cabometyx® (cabozantinib)
A tyrosine kinase inhibitor (TKI) used for the:
- Treatment of adults with advanced kidney cancer (advanced renal cell carcinoma – aRCC) as monotherapy or in combination with nivolumab
- Treatment of adults with liver cancer (hepatocellular carcinoma) previously treated with the medicine sorafenib.
- Treatment of adults with locally advanced or metastatic differentiated thyroid carcinoma (DTC), who are refractory or not eligible to radioactive iodine and who have progressed after prior systemic therapy
Package Insert
Cabometyx Package Insert
(729 KB)
Request medical information / report adverse event or product complaint
To request medical information on Ipsen’s products, report an adverse event or report a complaint, please email to medinfo.singapore@ipsen.com or product.complaints.sg@ipsen.com.
Adverse event reactions can also be reported directly to Ipsen’s local safety team, please email to pharmacovigilance.sg@ipsen.com.